Phase 2 trial of single agent docetaxel in platinum and paclitaxel-refractory ovarian cancer, fallopian tube cancer, and primary carcinoma of the peritoneum
- 1 December 2003
- journal article
- Published by Elsevier in Gynecologic Oncology
- Vol. 91 (3) , 573-576
- https://doi.org/10.1016/j.ygyno.2003.08.001
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a gynecologic oncology group studyGynecologic Oncology, 2003
- Phase II trial of weekly docetaxel in second-line therapy for nonsmall cell lung carcinomaCancer, 2001
- Weekly Docetaxel in Breast Cancer: Applying Clinical Data to Patient TherapyThe Oncologist, 2001
- Phase 2 Evaluation of Topotecan Administered on a 3-Day Schedule in the Treatment of Platinum- and Paclitaxel-Refractory Ovarian CancerGynecologic Oncology, 2000
- Phase 2 Trial of Liposomal Doxorubicin (40 mg/m2) in Platinum/Paclitaxel-Refractory Ovarian and Fallopian Tube Cancers and Primary Carcinoma of the PeritoneumGynecologic Oncology, 2000
- Randomized Intergroup Trial of Cisplatin-Paclitaxel Versus Cisplatin-Cyclophosphamide in Women With Advanced Epithelial Ovarian Cancer: Three-Year ResultsJNCI Journal of the National Cancer Institute, 2000
- Second-Line Treatment of Ovarian CancerThe Oncologist, 2000
- Phase II trials of docetaxel (taxotere®) in advanced ovarian cancer—an updated overviewEuropean Journal Of Cancer, 1997
- Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian CancerNew England Journal of Medicine, 1996
- Docetaxel: an Active New Drug for Treatment of Advanced Epithelial Ovarian CancerJNCI Journal of the National Cancer Institute, 1995